**BREATHTEC BIOMEDICAL INC.**Suite 890, 789 West Pender Street  
Vancouver, British Columbia, Canada V6C 1H2

## Breathtec Biomedical Engages DTG Partners to Advance Product Commercialization

**-- Medical product development consultancy aims to deliver proven, time-efficient and cost-effective expertise**

VANCOUVER, BRITISH COLUMBIA – September 27, 2016 – [Breathtec BioMedical, Inc](http://breathtecbiomedical.com/). (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “**Company**” or “**Breathtec**”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to announce the engagement of DTG Partners Consultants ([www.dtgpartners.ca](http://www.dtgpartners.ca)) to advance the efforts towards product commercialization.

DTG Partners is a medical product development consultancy specializing in helping innovative companies bring their products to market with a focused personalized approach to address individual client needs. The partners and associates at DTG have more than 70 years of experience in the development of specialized medical devices and products.

The company generates product development and regulatory strategies covering design, testing and manufacturing phases of complex medical devices. DTG further offers the preparation and implementation of ISO 13485 and FDA QSR compliant systems required for medical devices and combination products including design controls, technical files, production, process controls and other activities, as needed. Services include identification and optimization of manufacturing technologies; selection and validation of suppliers, management of required non-clinical studies, including biocompatibility, efficacy and safety. The company further manages regulatory agency interaction and license application preparation for multiple regions including US FDA, EU and Health Canada.

Partners Val Rubinchik M.Eng. P.Eng. and Rick Kjellbotn P.Eng., bring decades of experience in the areas of medical device design, testing, manufacturing, quality systems and regulatory submissions. Previous efforts include a number of therapeutic areas including ophthalmology, dermatology, interventional cardiology, gastroenterology and urology.

“We are excited by the opportunity to work with Breathtec on their cutting edge technology.” States DTG Partner Val Rubinchik. “We are committed to contributing our expertise towards bringing their diagnostic products through development to commercial release as quickly and efficiently as possible.”

Company CEO, Guy LaTorre comments, “The product development expertise Val and Rick bring to the table is critical at this stage of our development cycle. I’m happy to have them as part of our Team and really looking forward to working with both of them. We are very pleased to announce this engagement at this key juncture in the company’s growth as it reaffirms to our partners, stakeholders and shareholders alike a tangible and positive message that we are committed to delivering on our strategic timelines and goals for success.”

**ON BEHALF OF THE BOARD**

"Guy LaTorre"  
CEO & Director

**For further information, please contact:**

Kal Malhi

President & Director

[Breathtec BioMedical, Inc](http://breathtecbiomedical.com/)

or

Core Capital Partners   
Telephone: 604-566-9233  
Email: [investors@ccpartnersinc.com](mailto:investors@ccpartnersinc.com)

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release*. *This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*